{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:11:56Z","timestamp":1771661516963,"version":"3.50.1"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Objective<\/jats:title><jats:p>Xuebijing injection (XBJ) is a commonly used herbal medicine injection in China. However, the physical compatibility of XBJ with other intravenous drugs remains unclear. The purpose of this research is to evaluate physical compatibility of Xuebijing injection (XBJ) with 53 intravenous drugs (including 31 Chinese medicine injections and 22 chemicals) during simulated Y-site administration.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>Y-site administration was simulated in vitro by admixing 0.33 ml\/ml XBJ with an equal volume of other diluted 53 intravenous drugs, respectively. Physical compatibility including visual inspection, Tyndall beam, particle limits, turbidity, pH, chromacity value, spectroscopic absorption of 550 nm and 420 nm (A<jats:sub>550 nm<\/jats:sub>and A<jats:sub>420 nm<\/jats:sub>) were observed and assessed at 0, 1, 2, and 4 h. Physical compatibility was defined as all solutions with no color changes, no gas evolution, particulate formation and no Tyndall beam within 4 hours, turbidity changes &lt;0.5 nephelometric turbidity unit (NTU) compared to 0 h, particle limits allowed by the Chinese Pharmacopoeia (Ch.P) 2020 edition, pH changes &lt;10% compared to 0, chromacity value changes &lt;200 compared to 0 h, or photometrical changes of A<jats:sub>420 nm<\/jats:sub>&lt;0.0400 or A<jats:sub>550 nm<\/jats:sub>&lt;0.0100 compared to 0 h.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>XBJ was physically incompatible with 27 of the 53 intravenous drugs tested, 26 were compatible with XBJ for 4 h.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusions<\/jats:title><jats:p>XBJ should not be simultaneously co-administered with 27 of the 53 intravenous drugs during simulated Y-site. If coadministration was inevitable, flushing tube with NS or D5W before and after infusion of XBJ was needed. Assessment included visual inspection, Tyndall beam, turbidity measurement, particle counts, pH measurement, chromacity value measurement and absorption of A<jats:sub>550 nm<\/jats:sub>were proved to be valid and robust for the quality control of infusion and compatibility of Chinese herbal injection.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0299694","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T17:30:27Z","timestamp":1711128627000},"page":"e0299694","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physical compatibility of Xuebijing injection with 53 intravenous drugs during simulated Y-site administration"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5614-9862","authenticated-orcid":true,"given":"Tong","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4683-3476","authenticated-orcid":true,"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"pone.0299694.ref001","doi-asserted-by":"crossref","first-page":"153543","DOI":"10.1016\/j.phymed.2021.153543","article-title":"Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis","volume":"85","author":"W Zhou","year":"2021","journal-title":"Phytomedicine"},{"key":"pone.0299694.ref002","doi-asserted-by":"crossref","first-page":"113301","DOI":"10.1016\/j.jep.2020.113301","article-title":"The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms","volume":"265","author":"C Li","year":"2021","journal-title":"J Ethnopharmacol"},{"key":"pone.0299694.ref003","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1186\/1472-6882-14-498","article-title":"Protective effect of Xuebijing injection on paraquat-induced pulmonary injury via down-regulating the expression of p38 MAPK in rats","volume":"14","author":"W Liu M","year":"2014","journal-title":"BMC Complement Altern Med"},{"issue":"8","key":"pone.0299694.ref004","doi-asserted-by":"crossref","first-page":"e028664","DOI":"10.1136\/bmjopen-2018-028664","article-title":"Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial","volume":"9","author":"S Liu","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0299694.ref005","doi-asserted-by":"crossref","first-page":"949254","DOI":"10.1155\/2014\/949254","article-title":"Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation","volume":"2014","author":"Q Yin","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"issue":"7","key":"pone.0299694.ref006","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jamainternmed.2023.0780","article-title":"Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial","volume":"183","author":"S Liu","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"9","key":"pone.0299694.ref007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/adc.2009.174268","article-title":"Compatibility of drug infusions in the NICU","volume":"95","author":"B Kalikstad","year":"2010","journal-title":"Arch Dis Child"},{"issue":"11\u201312","key":"pone.0299694.ref008","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.nut.2005.09.001","article-title":"Beyond the bag horizon","volume":"21","author":"G Hardy","year":"2005","journal-title":"Nutrition"},{"issue":"2","key":"pone.0299694.ref009","first-page":"168","article-title":"Effect of intravenous infusion dead space on time to drug delivery in infants","volume":"31","author":"G Gregerson B","year":"2018","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"pone.0299694.ref010","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"Chinese Pharmacopoeia Commission","year":"2020"},{"issue":"8","key":"pone.0299694.ref011","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.clinthera.2020.06.005","article-title":"Intravenous Compatibility of Ceftazidime-Avibactam and Aztreonam Using Simulated and Actual Y-site Administration","volume":"42","author":"N O\u2019Donnell J","year":"2020","journal-title":"Clin Ther"},{"issue":"14","key":"pone.0299694.ref012","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration","volume":"75","author":"E Asempa T","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"pone.0299694.ref013","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.2146\/ajhp170123","article-title":"Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration","volume":"75","author":"L Monogue M","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"pone.0299694.ref014","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1272\/jnms.JNMS.2022_89-104","article-title":"Physical Compatibility of Nafamostat with Analgesics, Sedatives, and Muscle Relaxants for Treatment of Coronavirus Disease","volume":"88","author":"M Kondo","year":"2019","journal-title":"J Nippon Med Sch"},{"issue":"14","key":"pone.0299694.ref015","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2146\/ajhp090505","article-title":"Physical compatibility of 4% sodium citrate with selected antimicrobial agents","volume":"67","author":"B Dotson","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"pone.0299694.ref016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pharmaceutics13010021","article-title":"Medication Safety in Intravenous Therapy: A Compatibility Study of Clonidine with Drugs Frequently Used in Intensive Care","volume":"13","author":"K Koller A","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"pone.0299694.ref017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clinthera.2017.12.007","article-title":"Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration","volume":"40","author":"M Kidd J","year":"2018","journal-title":"Clin Ther"},{"issue":"04","key":"pone.0299694.ref018","first-page":"271","article-title":"Study on Instrumental Method of Clarity Examination","volume":"17","author":"D Li W","year":"2016","journal-title":"Drug Standards Of China"},{"issue":"4","key":"pone.0299694.ref019","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0018578719893376","article-title":"Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications","volume":"56","author":"M Lee T","year":"2021","journal-title":"Hosp Pharm"},{"issue":"1","key":"pone.0299694.ref020","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.2146\/ajhp150762","article-title":"Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration","volume":"74","author":"K Thabit A","year":"2017","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"pone.0299694.ref021","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0018578719844168","article-title":"Compatibility of Y-Site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs","volume":"55","author":"J Lessard J","year":"2020","journal-title":"Hosp Pharm"},{"issue":"5","key":"pone.0299694.ref022","doi-asserted-by":"crossref","first-page":"e0233335","DOI":"10.1371\/journal.pone.0233335","article-title":"Simultaneous administration of imipenem\/cilastatin\/relebactam with selected intravenous antimicrobials, a stewardship approach","volume":"15","author":"M Ghazi I","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0299694.ref023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5114\/ait.2020.92684","article-title":"Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection","volume":"52","author":"S Hanifah","year":"2020","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"3","key":"pone.0299694.ref024","doi-asserted-by":"crossref","first-page":"353","DOI":"10.22146\/ijp.2262","article-title":"Management of Y-Site Incompatibility of Intravenous Medication: A Scoping Review","volume":"33","author":"S Hanifah","year":"2022","journal-title":"Indonesian J Pharm"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0307827","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T22:14:23Z","timestamp":1731622463000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299694"}},"subtitle":[],"editor":[{"given":"Adeel","family":"Sattar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299694","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0307827","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]}}}